Patamostat is a potent protease inhibitor with potential therapeutic application in the treatment of acute pancreatitis. It effectively inhibits trypsin (IC50 = 39 nM), plasmin (IC50 = 950 nM), and thrombin (IC50 = 1.9 μM). In animal models, intravenous infusion of Patamostat significantly reduced mortality in a dose-dependent manner following induction of pancreatitis, suppressed elevated serum trypsin and lipase activities, and improved multiple pathological parameters including survival rate, serum and ascitic fluid amylase levels, plasma endotoxin levels, and serum fibrin degradation product (FDP) levels.